Press Releases

Enveda Appoints Christopher K. Porter, MBA, JD as Senior Vice President, Clinical Operations
April 15, 2026
Read More
Enveda Reports Positive Results for ENV-294 in a Phase 1b Clinical Trial of Patients with Moderate-to-Severe Atopic Dermatitis
March 31, 2026
Read More
Enveda Advances Third Asset to the Clinic With US FDA IND Clearance and Phase 1 Initiation of ENV-6946, a First-in-Class Oral “Multi-Biologic in a Pill” for Inflammatory Bowel Disease
December 23, 2025
Read More
Enveda Announces US FDA IND Clearance and First Patient Dosed in Phase 1 Trial of ENV-308, a First-in-Class Oral Therapy for Obesity; Appoints Nadeem Sarwar, Ph.D., MPharm, MPhil, to Lead…
December 17, 2025
Read More
Enveda Initiates Phase 2 Clinical Trials of ENV-294, a First-in-Class Oral Therapy in Atopic Dermatitis and Asthma
December 9, 2025
Read More
Enveda Reports Favorable Phase 1 Safety for Novel Oral Anti-Inflammatory, Launches Phase 1b Trial in Atopic Dermatitis
May 28, 2025
Read More
Enveda Gains Backing from Sanofi to Advance AI-Driven Drug Discovery to Clinical Trials Bringing Total Series C Financing to $150M
February 26, 2025
Read More
Enveda Expands into Asthma with First-in-Class Lead Asset ENV-294 and Assembles World-Class Advisory Board
February 5, 2025
Read More
Enveda Welcomes Jason Kim as Chief Financial Officer
January 10, 2025
Read More
Enveda Closes $130M Series C Funding to Deliver Multiple Clinical Readouts from a Pipeline of 10 Development Candidates
November 21, 2024
Read More
Enveda Announces First Candidate Discovered From Nature Using AI Advances to Clinical Trials
November 13, 2024
Read More
Enveda Biosciences Hires Chief Medical Officer to Advance Its Rich Pipeline of Therapeutic Programs into the Clinic
August 1, 2024
Read More
Enveda Raises $150M Series D Funding to Reach Unicorn Status, Enrolls First Patient in Lead Program, and Adds Mikael Dolsten to Board of Directors
September 4, 2025
Read More
Enveda Biosciences Announces $55M in New Funding to Accelerate Platform and Advance Multiple Candidates to Clinical Trials
June 14, 2024
Read More
Enveda Biosciences Announces Microsoft Collaboration and Reveals Foundation Model to “Read and Translate” Chemistry
May 29, 2024
Read More
Enveda Biosciences unveils new AI algorithm to unlock nature’s chemical code
June 21, 2023
Read More
Enveda Biosciences Announces Oversubscribed Series B1 Bringing Total Round to US$119 Million
April 20, 2023
Read More
Enveda Biosciences Closes $68-million Combined Series B Equity and Debt Financing
December 21, 2022
Read More
Enveda Biosciences Closes $51M Series A Financing Led by Lux Capital
June 22, 2021
Read More
Copyright ©2026 ENVEDA All rights reserved
PRIVACY POLICY |
TERMS OF SERVICE
Site by Maven Creative